

26-07-2001  
PCT/EP00/06905  
20392P WO/WWJFpu


- 22 -

EP0006905

# Claims

5

1. A compound of the general structural formula (I):



- 10 wherein  $X^{21}-X^{30}$  are monomeric building blocks, preferably aminocarboxylic acid residues and are derived from a structure in which  $X^{21}$  = D-Cys,  $X^{22}$  = Asn,  $X^{23}$  = Lys,  $X^{24}$  = Tyr,  $X^{25}$  = Phe,  $X^{26}$  = Ser,  $X^{27}$  = Asn,  $X^{28}$  = Ile,  $X^{29}$  = Cys and  $X^{30}$  = Trp, Y is a  
15 spacer and m is 0 or 1, and the monomeric building blocks are linked via  $-\text{CONR}^1$  or  $-\text{NR}^1\text{CO}$  bonds, in which  $R^1$  in each case independently is hydrogen, methyl or ethyl, and pharmaceutically acceptable salts and derivatives thereof,  
20 with the proviso that at least one of the amino acid residues  $X^{21}-X^{30}$  of the lead structure is replaced by one of the amino acid residues listed below:

- 25  $X^{21}$ : Asp, Glu, 2,3-diaminopropionic acid (Dap), 2,4-diaminobutyric acid (Dab), D-penicillanine (D-Pen), allylglycine (Alg), ornithine (Orn), Lys;  
 $X^{22}$ : Asp, Glu;  
30  $X^{23}$ : Dab, Dap, His, citrulline (Cit), homocitrulline (Hci), norleucine (Nle);  
 $X^{24}$ : homophenylalanine (Hph), 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic), thienylalanine (Thi), Trp,  
35 phenylglycin (Phg), 1-naphthylalanine (1-Nal), 2-naphthylalanine (2-Nal), Cha (cyclohexylalanine);  
 $X^{25}$ : Trp, Tic, Thi, Hph, Phg;

AMENDED SHEET

Art. 34.

26-07-2001

- 23 -

EP0006905

- 5       $X^{26}$ : Val;  
           $X^{27}$ : Asp, Glu;  
           $X^{28}$ : Cha, 2-aminobutyric acid (Abu), tert-leucine  
                     (Tle),  $\alpha$ -aminoisobutyric acid (Aib);  
           $X^{29}$ : Asp, Glu, Dap, Dab, Alg, D-Pen, Orn, Lys;


2.      The compound as claimed in claim 1,  
          **characterized in that**  
          at least one of the amino acid residues  $X^{21}$ - $X^{30}$  of  
 10      the lead structure has one of the meanings listed  
          below:

- $X^{21}$ : D-Pen;  
           $X^{23}$ : Dap, Dab, Cit, Hci, Nle, His;  
           $X^{24}$ : Thi, Hph, Phg, 1-Nal, 2-Nal, Cha;  
 15       $X^{25}$ : Thi;  
           $X^{27}$ : Asp;  
           $X^{28}$ : Val, Cha.

3.      The compound as claimed in claim 1,  
 20      **characterized in that**  
          at least one of the amino acid residues  $X^{21}$ - $X^{30}$  of  
          the lead structure has one of the meanings listed  
          below:

- $X^{21}$ : D-Pen;  
 25       $X^{23}$ : Dab, Nle, Cit, Hci;  
           $X^{24}$ : 1-Nal, 2-Nal, Cha;  
           $X^{25}$ : Thi;  
           $X^{28}$ : Cha.

30      4.      A compound of the general structural formula (I):



35      wherein  $X^{21}$ - $X^{30}$  are monomeric building blocks,  
          preferably aminocarboxylic acid residues and are  
          derived from a structure in which  $X^{21}$  = D-Cys,  $X^{22}$   
          = Asn,  $X^{23}$  = Dap, Dab or Nle,  $X^{24}$  = Tyr,  $X^{25}$  = Phe,

26-07-2001

- 24 -

EP0006905

$X^{26}$  = Ser,  $X^{27}$  = Asn,  $X^{28}$  = Ile,  $X^{29}$  = Cys and  $X^{30}$  = Trp, Y is a spacer and m is 0 or 1, and the monomeric building blocks are linked via  $-\text{CONR}^1$  or  $-\text{NR}^1\text{CO}$  bonds, in which  $R^1$  in each case independently is hydrogen, methyl or ethyl, and pharmaceutically acceptable salts and derivatives thereof.

5

5. The compound as claimed in any of the preceding claims,

**characterized in that**

at least 2 of the amino acid residues  $X^{22}$ ,  $X^{23}$ ,  $X^{24}$ ,  $X^{25}$ ,  $X^{26}$ ,  $X^{27}$ ,  $X^{28}$  and  $X^{30}$  have the same side chain as an amino acid at the same position in the native uPA sequence.

15

6. The compound as claimed in claim 5,

**characterized in that**

at least 2 of the amino acid residues  $X^{24}$ ,  $X^{25}$ ,  $X^{28}$  and  $X^{30}$  have the same side chain as in the native uPA sequence.

20

7. A pharmaceutical composition, which contains as active substance at least one compound as claimed in any of claims 1 to 6, where appropriate together with pharmaceutically common carriers, excipients or diluents.

25

8. The use of a compound as claimed in any of claims 1 to 6 for preparing a uPAR antagonist.

30

9. The use as claimed in claim 8 for controlling disorders associated with uPAR expression, in particular for controlling tumors.

35

10. The use of a compound as claimed in any of claims 1 to 6 for preparing a targeting vehicle for cells expressing uPAR.

Art. 34

26-07-2001

- 25 -

EP0006905

11. The use of a compound as claimed in any of claims 1 to 6 for preparing an angiogenesis inhibitor.

5